
First-in-class GIP antagonist for obesity enters Phase I trials
Helicore Biopharma has reported dosing the first participant in its Phase I study of HCR-188 for the treatment of obesity. HCR-188 is a first-in-class monoclonal antibody (mAb) designed to bind to circulating glucose-dependent insulinotropic peptide (GIP) ligand, unlike antibodies that bind the GIP receptor (GIP… Read More

